---
figid: PMC6945546__13023_2019_1281_Fig3_HTML
figlink: pmc/articles/PMC6945546/figure/Fig3/
number: F3
caption: Future treatments for HHT. The HHT-causing mutations of genes encoding components
  of the BMP9/BMP10 signaling pathway (indicated by red asterisks), result in decreased
  downstream signaling (indicated by thinner arrows than in Fig. ) and increased activity
  of the VEGF and ANGPT2 signaling pathways (indicated by thicker arrows than in Fig.
  ). Several drugs that target these pathways are already in use in clinical trials
  (blue boxes) or under evaluation in preclinical studies (parma boxes) for HHT treatment.
  Currently evaluated HHT treatments target VEGF via anti-VEGF antibodies (bevacizumab)
  or VEGFR2 tyrosine kinase inhibitors (VEGFR2-TKI such as pazopanib). Tacrolimus
  and sirolimus were identified through recent high-throughput screening of FDA-approved
  drugs as activators of ALK1 (and ALK3) signaling. They are under phase I/II trials
  as clinical treatments for HHT. Preclinical studies are investigating the beneficial
  effects of anti-ANGPT2 antibodies (LC-10) and PI3-kinase inhibitors (wortmannin
  or LY294002). As shown on this cartoon, all these treatments aim at restoring the
  balance between the BMP9 pathway and the VEGF/ANGPT2 pathways in order to re-establish
  vascular quiescence
pmcid: PMC6945546
papertitle: Future treatments for hereditary hemorrhagic telangiectasia.
reftext: Florian Robert, et al. Orphanet J Rare Dis. 2020;15:4.
pmc_ranked_result_index: '45206'
pathway_score: 0.9738637
filename: 13023_2019_1281_Fig3_HTML.jpg
figtitle: Future treatments for HHT
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6945546__13023_2019_1281_Fig3_HTML.html
  '@type': Dataset
  description: Future treatments for HHT. The HHT-causing mutations of genes encoding
    components of the BMP9/BMP10 signaling pathway (indicated by red asterisks), result
    in decreased downstream signaling (indicated by thinner arrows than in Fig. )
    and increased activity of the VEGF and ANGPT2 signaling pathways (indicated by
    thicker arrows than in Fig. ). Several drugs that target these pathways are already
    in use in clinical trials (blue boxes) or under evaluation in preclinical studies
    (parma boxes) for HHT treatment. Currently evaluated HHT treatments target VEGF
    via anti-VEGF antibodies (bevacizumab) or VEGFR2 tyrosine kinase inhibitors (VEGFR2-TKI
    such as pazopanib). Tacrolimus and sirolimus were identified through recent high-throughput
    screening of FDA-approved drugs as activators of ALK1 (and ALK3) signaling. They
    are under phase I/II trials as clinical treatments for HHT. Preclinical studies
    are investigating the beneficial effects of anti-ANGPT2 antibodies (LC-10) and
    PI3-kinase inhibitors (wortmannin or LY294002). As shown on this cartoon, all
    these treatments aim at restoring the balance between the BMP9 pathway and the
    VEGF/ANGPT2 pathways in order to re-establish vascular quiescence
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ACVRL1
  - BMP10
  - GDF2
  - ANGPT2
  - VEGFD
  - VEGFB
  - PGF
  - VEGFA
  - VEGFC
  - ENG
  - TEK
  - KDR
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - PLCG1
  - PLCG2
  - SRC
  - SMAD1
  - SMAD2
  - SMAD5
  - SMAD6
  - SMAD9
  - SMAD3
  - SMAD4
  - SMAD7
  - PTEN
  - AKT2
  - AKT3
  - AKT1
  - MAPK3
  - MAPK1
  - MAPK14
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK9
  - MAPK10
  - MAK
  - FLT1
  - Tacrolimus
  - Sirolimus
  - HHT
genes:
- word: HHT
  symbol: HHT
  source: hgnc_alias_symbol
  hgnc_symbol: ACVRL1
  entrez: '94'
- word: BMP10
  symbol: BMP10
  source: hgnc_symbol
  hgnc_symbol: BMP10
  entrez: '27302'
- word: BMP9
  symbol: BMP9
  source: hgnc_alias_symbol
  hgnc_symbol: GDF2
  entrez: '2658'
- word: ANGPT2
  symbol: ANGPT2
  source: hgnc_symbol
  hgnc_symbol: ANGPT2
  entrez: '285'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: ENG*
  symbol: ENG
  source: hgnc_symbol
  hgnc_symbol: ENG
  entrez: '2022'
- word: Tie2
  symbol: TIE2
  source: hgnc_alias_symbol
  hgnc_symbol: TEK
  entrez: '7010'
- word: VEGFR2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD1
  entrez: '4086'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD2
  entrez: '4087'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD5
  entrez: '4090'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD6
  entrez: '4091'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD9
  entrez: '4093'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD3
  entrez: '4088'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: Smad
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD7
  entrez: '4092'
- word: Smad1/5/9
  symbol: SMAD9
  source: hgnc_symbol
  hgnc_symbol: SMAD9
  entrez: '4093'
- word: Smad1/5/9
  symbol: SMAD5
  source: hgnc_symbol
  hgnc_symbol: SMAD5
  entrez: '4090'
- word: Smad1/5/9
  symbol: SMAD1
  source: hgnc_symbol
  hgnc_symbol: SMAD1
  entrez: '4086'
- word: Smad4
  symbol: SMAD4
  source: hgnc_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: Smad4*
  symbol: SMAD4
  source: hgnc_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAРК
  symbol: MAK
  source: hgnc_symbol
  hgnc_symbol: MAK
  entrez: '4117'
- word: ANGPT2,
  symbol: ANGPT2
  source: hgnc_symbol
  hgnc_symbol: ANGPT2
  entrez: '285'
- word: ANGPT2,VEGFR1,.
  symbol: ANGPT2
  source: hgnc_symbol
  hgnc_symbol: ANGPT2
  entrez: '285'
- word: VEGFR1,
  symbol: VEGFR1
  source: hgnc_alias_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
chemicals:
- word: Tacrolimus
  source: MESH
  identifier: D016559
- word: Sirolimus
  source: MESH
  identifier: D020123
diseases:
- word: HHT
  source: MESH
  identifier: D013683
figid_alias: PMC6945546__F3
redirect_from: /figures/PMC6945546__F3
figtype: Figure
---
